Gentile, Marino
 Distribuzione geografica
Continente #
NA - Nord America 523
EU - Europa 326
AS - Asia 36
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 891
Nazione #
US - Stati Uniti d'America 523
SE - Svezia 164
IT - Italia 73
IE - Irlanda 41
FR - Francia 18
DE - Germania 14
IN - India 13
CN - Cina 11
AU - Australia 4
HK - Hong Kong 4
KR - Corea 3
TR - Turchia 3
BE - Belgio 2
CH - Svizzera 2
GR - Grecia 2
RU - Federazione Russa 2
UA - Ucraina 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AT - Austria 1
CZ - Repubblica Ceca 1
EU - Europa 1
GB - Regno Unito 1
IQ - Iraq 1
IR - Iran 1
LT - Lituania 1
NL - Olanda 1
PL - Polonia 1
Totale 891
Città #
Chandler 183
New York 38
Ashburn 36
Dublin 33
Princeton 21
Milan 17
San Mateo 16
Wilmington 15
Marseille 13
Florence 12
Dearborn 9
Pune 9
Norwalk 7
Trieste 7
Boston 6
Garden City 6
Houston 6
Fairfield 5
Redwood City 5
Beijing 4
Benalla 4
Bologna 4
Cattolica 4
Hong Kong 4
Redmond 4
Seattle 4
Vicopisano 4
Bremen 3
Falls Church 3
Fremont 3
Hefei 3
Izmir 3
Jacksonville 3
Los Angeles 3
Seoul 3
Washington 3
Andover 2
Bari 2
Brussels 2
Chicago 2
Oshkosh 2
Rome 2
Turin 2
Venice 2
Verona 2
Ann Arbor 1
Asti 1
Atlanta 1
Augusta 1
Berlin 1
Bern 1
Boardman 1
Botzingen 1
Brdo 1
Clearwater 1
Ferrara 1
Guidonia Montecelio 1
Gurgaon 1
Kish 1
Lausanne 1
Millbury 1
Mountain View 1
Naaldwijk 1
Nanchang 1
Nanjing 1
Naples 1
Pomigliano D'arco 1
Riano 1
Saint Petersburg 1
San Francisco 1
Santarcangelo di Romagna 1
Tianjin 1
Vienna 1
Woodbridge 1
Totale 550
Nome #
Adult phenotype in Koolen-de Vries/KANSL1 haploinsufficiency syndrome 75
Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study 59
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 56
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 55
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 53
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 50
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death 47
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. 43
CD49d promotes disease progression in chronic lymphocytic leukemia: New insights from CD49d bimodal expression 43
Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib 39
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 38
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group 38
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies 37
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group 37
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study 37
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 36
Clinical Features of Patients with Cervical Artery Dissection and Fibromuscular Dysplasia 33
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report 29
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 29
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus 28
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report 24
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? 18
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL 12
Totale 916
Categoria #
all - tutte 4.888
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.888


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20197 0 0 0 0 0 0 0 0 0 0 7 0
2019/202026 2 1 1 0 5 6 2 2 3 0 4 0
2020/202128 0 0 0 6 0 0 9 0 1 9 1 2
2021/2022233 5 0 49 32 27 5 2 26 7 7 48 25
2022/2023422 58 67 30 64 18 66 15 25 55 3 12 9
2023/2024200 9 59 11 12 15 59 14 12 1 8 0 0
Totale 916